Hilla Giladi
Overview
Explore the profile of Hilla Giladi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
591
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shmuelian Z, Warszawer Y, Or O, Arbel-Alon S, Giladi H, Tsadok M, et al.
J Med Virol
. 2022 Nov;
95(1):e28274.
PMID: 36324272
During the COVID-19 pandemic, postexposure-vaccine-prophylaxis is not a practice. Following exposure, only patient isolation is imposed. Moreover, no therapeutic prevention approach is applied. We asked whether evidence exists for reduced...
2.
Rosenberg N, Van Haele M, Lanton T, Brashi N, Bromberg Z, Adler H, et al.
J Hepatol
. 2022 Aug;
77(6):1631-1641.
PMID: 35988690
Background & Aims: Primary liver cancers include hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (CCA) and combined HCC-CCA tumors (cHCC-CCA). It has been suggested, but not unequivocally proven, that hepatic progenitor cells...
3.
Harari-Steinfeld R, Gefen M, Simerzin A, Zorde-Khvalevsky E, Rivkin M, Ella E, et al.
Cancers (Basel)
. 2021 Jan;
13(3).
PMID: 33499244
The -derived microRNA-675 (miR-675) has been implicated as both tumor promoter and tumor suppressor and also plays a role in liver inflammation. We found that miR-675 promotes cell death in...
4.
Chai C, Giladi H, Galun E
Gastroenterology
. 2021 Jan;
160(5):1882-1883.
PMID: 33453232
No abstract available.
5.
Chai C, Cox B, Yaish D, Gross D, Rosenberg N, Amblard F, et al.
Gastroenterology
. 2020 May;
159(3):999-1014.e9.
PMID: 32450149
Background & Aims: Development of nonalcoholic steatohepatitis (NASH) is associated with reductions in hepatic microRNA122 (MIR122); the RAR related orphan receptor A (RORA) promotes expression of MIR122. Increasing expression of...
6.
Chai C, Galun E, Giladi H
Gastroenterology
. 2018 Mar;
154(5):1553-1554.
PMID: 29526723
No abstract available.
7.
Chai C, Rivkin M, Berkovits L, Simerzin A, Zorde-Khvalevsky E, Rosenberg N, et al.
Gastroenterology
. 2017 Aug;
153(5):1404-1415.
PMID: 28802563
Background & Aims: Effective treatments are needed for hepatic steatosis characterized by accumulation of triglycerides in hepatocytes, which leads to hepatocellular carcinoma. MicroRNA 122 (MIR122) is expressed only in the...
8.
Rivkin M, Simerzin A, Zorde-Khvalevsky E, Chai C, Yuval J, Rosenberg N, et al.
Gastroenterology
. 2016 Aug;
151(5):999-1010.e3.
PMID: 27477940
Background & Aims: Anemia is associated commonly with acute and chronic inflammation, but the mechanisms of their interaction are not clear. We investigated whether microRNA 122 (MIR122), which is generated...
9.
Simerzin A, Zorde-Khvalevsky E, Rivkin M, Adar R, Zucman-Rossi J, Couchy G, et al.
Hepatology
. 2016 Jun;
64(5):1623-1636.
PMID: 27302319
Conclusion: miR-122*, the passenger strand of miR-122, regulates the activity of p53 by targeting Mdm2. Importantly, similarly to miR-122, miR-122* is significantly down-regulated in human HCC. We therefore propose that...
10.
Zorde Khvalevsky E, Gabai R, Rachmut I, Horwitz E, Brunschwig Z, Orbach A, et al.
Proc Natl Acad Sci U S A
. 2013 Dec;
110(51):20723-8.
PMID: 24297898
Pancreatic ductal adenocarcinoma (PDA) represents an unmet therapeutic challenge. PDA is addicted to the activity of the mutated KRAS oncogene which is considered so far an undruggable therapeutic target. We...